ATE371437T1 - Peptidische nanoteilchen als arzneimittelabgabe- und antigen-display-systeme - Google Patents

Peptidische nanoteilchen als arzneimittelabgabe- und antigen-display-systeme

Info

Publication number
ATE371437T1
ATE371437T1 AT04711429T AT04711429T ATE371437T1 AT E371437 T1 ATE371437 T1 AT E371437T1 AT 04711429 T AT04711429 T AT 04711429T AT 04711429 T AT04711429 T AT 04711429T AT E371437 T1 ATE371437 T1 AT E371437T1
Authority
AT
Austria
Prior art keywords
peptidic
nanoparticles
functionalized
nanoparticle
antigen
Prior art date
Application number
AT04711429T
Other languages
German (de)
English (en)
Inventor
Peter Burkhard
Original Assignee
Peter Burkhard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32864945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE371437(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Peter Burkhard filed Critical Peter Burkhard
Application granted granted Critical
Publication of ATE371437T1 publication Critical patent/ATE371437T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04711429T 2003-02-17 2004-02-16 Peptidische nanoteilchen als arzneimittelabgabe- und antigen-display-systeme ATE371437T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03003551 2003-02-17

Publications (1)

Publication Number Publication Date
ATE371437T1 true ATE371437T1 (de) 2007-09-15

Family

ID=32864945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04711429T ATE371437T1 (de) 2003-02-17 2004-02-16 Peptidische nanoteilchen als arzneimittelabgabe- und antigen-display-systeme

Country Status (6)

Country Link
US (1) US8575110B2 (enExample)
EP (1) EP1594469B1 (enExample)
JP (1) JP4509999B2 (enExample)
AT (1) ATE371437T1 (enExample)
DE (1) DE602004008582T2 (enExample)
WO (1) WO2004071493A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5022028B2 (ja) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート
US20040236414A1 (en) * 2003-05-23 2004-11-25 Brar Balbir S. Devices and methods for treatment of stenotic regions
US7226473B2 (en) * 2003-05-23 2007-06-05 Brar Balbir S Treatment of stenotic regions
JP5117191B2 (ja) * 2004-10-01 2013-01-09 ミダテック リミテッド 抗原及びアジュバントを含むナノ粒子、並びに免疫原性構造
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
NZ573622A (en) 2006-06-12 2011-12-22 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US8889117B2 (en) * 2007-02-15 2014-11-18 Yale University Modular nanoparticles for adaptable vaccines
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
WO2009042895A2 (en) * 2007-09-26 2009-04-02 Dana-Farber Cancer Institute, Inc. Reagents for inducing an immune response
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
RU2540871C2 (ru) * 2008-02-01 2015-02-10 Альфа-О Пептидес Аг Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин
KR101803099B1 (ko) 2008-05-16 2017-11-30 타이가 바이오테크놀로지스, 인코포레이티드 항체 및 그 제조 방법
EP2313108A4 (en) * 2008-06-30 2013-06-12 Us Army As Represented By The Secretary Of The Army MALARIA VACCINE FROM SELF-ORGANIZING POLYPEPTIDE NANOTEHICLES
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
EP2397547A4 (en) 2009-02-10 2012-09-05 Univ Ryukyus DRUG CARRIER AND ADJUVANT AND VACCINE USING EACH
CA2759332A1 (en) * 2009-04-21 2010-10-28 Selecta Biosciences, Inc. Immunonanotherapeutics providing a th1-biased response
WO2010138193A2 (en) * 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
AU2010293059B2 (en) * 2009-08-26 2017-03-16 Selecta Biosciences, Inc. Compositions that induce T cell help
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EP2611466B1 (en) 2010-08-30 2019-06-12 President and Fellows of Harvard College Shear controlled release of thrombolytic therapies for stenotic lesions
CN103501812A (zh) 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于过敏症治疗的致耐受性合成纳米载体
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
CA2851917A1 (en) 2011-10-12 2013-04-18 Alpha-O Peptides Ag Self-assembling peptide nanoparticles as vaccines against infection with norovirus
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
EP3760223A1 (en) 2013-04-03 2021-01-06 N-Fold Llc Nanoparticle composition for desensitizing a subject to peanut allergens
CA2910584A1 (en) 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells
TW201511774A (zh) * 2013-09-18 2015-04-01 Iner Aec Executive Yuan 放射性標誌之主動標靶性醫藥組合物及其用途
US10188136B2 (en) 2016-02-16 2019-01-29 Indian Institute Of Science Education And Research Hydrophobin mimics: process for preparation thereof
EP4242298A2 (en) * 2016-12-02 2023-09-13 Taiga Biotechnologies, Inc. Nanoparticle formulations
KR101955928B1 (ko) * 2016-12-30 2019-03-08 경상대학교산학협력단 먹장어 유래 vlrb 단백질의 소수성 테일 도메인을 포함하는 다량체 다가 중합체
WO2018154010A1 (en) 2017-02-23 2018-08-30 Alpha-O Peptides Ag Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018172447A1 (en) 2017-03-23 2018-09-27 Alpha-O Peptides Ag Self-assembling protein nanoparticles with built-in six-helix bundle proteins
US11213582B2 (en) 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
AU2020274117A1 (en) 2019-05-14 2021-12-02 Taiga Biotechnologies, Inc. Compositions and methods for treating T cell exhaustion
EP4026558A4 (en) * 2019-08-27 2022-10-19 Tokyo Institute of Technology COMPOSITE PROTEIN MONOMER HAVING A NON-STRUCTURAL PROTEIN OF VIRUS SUPPORTED THEREOF, AGGREGATE OF COMPOSITE PROTEIN MONOMER, AND COMPONENT VACCINE COMPRISING AGGREGATE AS ACTIVE INGREDIENT
CN111150842B (zh) * 2019-12-31 2023-09-05 优锐生物医药科技(深圳)有限公司 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用
CN111150841B (zh) * 2019-12-31 2023-08-15 优锐生物医药科技(深圳)有限公司 一种主动免疫调控微粒及其制备方法和应用
JP2023522249A (ja) * 2020-04-22 2023-05-29 ビオンテック・ソシエタス・エウロパエア コロナウイルスワクチン
KR20230088732A (ko) 2020-09-29 2023-06-20 옥스포드 유니버시티 이노베이션 리미티드 뇌졸중 치료
WO2022106860A1 (en) 2020-11-20 2022-05-27 Pécsi Tudományegyetem Recombinant peptides for use in therapy
WO2023108026A2 (en) 2021-12-08 2023-06-15 Oakgrove Bio Llc Biological production of histidine-rich peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US5041385A (en) * 1986-11-01 1991-08-20 Oxford Gene Systems Limited Vector expressing fusion proteins and particles
US5877279A (en) * 1994-10-13 1999-03-02 Nanoframes, Llc Materials for the production of nanometer structures and use thereof
US6756039B1 (en) * 1999-05-10 2004-06-29 The Regents Of The University Of California Self assembling proteins
WO2001000010A1 (en) * 1999-06-25 2001-01-04 Kondejewski Leslie H Polypeptide compositions formed using a coiled-coil template and methods of use
JP4085231B2 (ja) * 2000-02-28 2008-05-14 株式会社ビークル タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法

Also Published As

Publication number Publication date
DE602004008582T2 (de) 2008-05-21
US20070014804A1 (en) 2007-01-18
JP4509999B2 (ja) 2010-07-21
WO2004071493A1 (en) 2004-08-26
JP2006519781A (ja) 2006-08-31
US8575110B2 (en) 2013-11-05
EP1594469B1 (en) 2007-08-29
DE602004008582D1 (de) 2007-10-11
EP1594469A1 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
ATE371437T1 (de) Peptidische nanoteilchen als arzneimittelabgabe- und antigen-display-systeme
Haupt et al. Molecularly imprinted polymers: antibody mimics for bioimaging and therapy
Hu et al. Acid-resistant and physiological pH-responsive DNA hydrogel composed of A-motif and i-motif toward oral insulin delivery
Wang et al. Micro/nanomachines and living biosystems: from simple interactions to microcyborgs
Lin et al. Well-ordered mesoporous silica nanoparticles as cell markers
Sardar et al. Asymmetrically functionalized gold nanoparticles organized in one-dimensional chains
KR20240112769A (ko) 로봇, 장비, 장치, 시설, 수단, 자재, 재료, 물질, 물품, 물체, 시스템
Tan et al. Chitosan nanoparticle-based delivery of fused NKG2D–IL-21 gene suppresses colon cancer growth in mice
JP2006519781A5 (enExample)
Kim et al. Transformative impact of nanocarrier‐mediated drug delivery: overcoming biological barriers and expanding therapeutic horizons
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
Saha et al. Synthesis of nanobioconjugates with a controlled average number of biomolecules between 1 and 100 per nanoparticle and observation of multivalency dependent interaction with proteins and cells
Zeng et al. Receptor‐specific delivery of protein antigen to dendritic cells by a nanoemulsion formed using top‐down non‐covalent click self‐assembly
JP2008543278A5 (enExample)
HRP20220230T1 (hr) Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
CY1108444T1 (el) (πολυ)αμινοακεταμιδικα παραγωγα της επιποδοφυλλοτοξινης, η μεθοδος παρασκευης τους και οι εφαρμογες τους στη θεραπευτικη ως αντικαρκινικων παραγοντων
KR20230129961A (ko) AI, IT, IoT 로봇, 드론, 장비, 장치, 시설, 작업, 공사, 건설, 건축, 시스템, 안전관리, 공사관리, 작업관리
KR20240056998A (ko) 장치, 장비, 자재, 재료, 물품, 물체, 물질, 작업, 제조, 공사, 정화, 청정, 처리, 살균, 소독, 수단, 시설, 건물, 구조물, 드론, 배터리, 파워뱅크, 3d프린터, 모빌리티, 메타버스
Park et al. Two‐Step Protein Self‐Assembly in the Extracellular Matrix
ATE458472T1 (de) In vivo targeting von dendritischen zellen
HRP20192262T1 (hr) Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
ATE304709T1 (de) Substanzen mit verzweigten linkermolekülen
Soshee et al. General in vitro method to analyze the interactions of synthetic polymers with human antibody repertoires
Lv et al. Demonstration of intracellular trafficking, cytosolic bioavailability, and target manipulation of an antibody delivery platform
Ren et al. Streptavidin− biotin binding in the presence of a polymer spacer. A theoretical description

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties